Granted Patent
B2
US 12,465,643 · App. 19/068,133 · Granted Nov 11, 2025
Ras inhibitors
Inventors:
Elena S. Koltun (Foster City, CA); James Cregg (Belmont, CA); Yang Liu (Foster City, CA); Adrian L. Gill (Atherton, CA)
Assignee:
Revolution Medicines, Inc.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
The disclosure features macrocyclic compounds, and pharmaceutical compositions and protein complexes thereof, capable of inhibiting Ras proteins, and their uses in the treatment of cancers.
Claims (3)
1 . A compound having the structure of:
or a pharmaceutically acceptable salt thereof, wherein at least one hydrogen atom of the compound is replaced by deuterium.
2 . A pharmaceutical composition comprising a compound of claim 1 , or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient or carrier.
Assignments (19)
SECURITY INTEREST
Recorded Mar 26, 2026
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 074200/0231 →
SECURITY INTEREST
Recorded Mar 26, 2026
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 074200/0837 →
SECURITY INTEREST
Recorded Mar 26, 2026
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 074200/0905 →
SECURITY INTEREST
Recorded Mar 26, 2026
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 074200/0941 →
SECURITY INTEREST
Recorded Mar 26, 2026
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 074200/0960 →
SECURITY INTEREST
Recorded Mar 26, 2026
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 074200/0870 →
SECURITY INTEREST
Recorded Mar 26, 2026
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 074196/0341 →
SECURITY INTEREST
Recorded Mar 26, 2026
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 074197/0721 →
SECURITY INTEREST
Recorded Mar 26, 2026
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 074199/0834 →
SECURITY INTEREST
Recorded Mar 26, 2026
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 074200/0048 →
SECURITY INTEREST
Recorded Mar 26, 2026
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 074200/0127 →
SECURITY INTEREST
Recorded Mar 26, 2026
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 074200/0155 →
SECURITY INTEREST
Recorded Mar 26, 2026
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 074200/0267 →
SECURITY INTEREST
Recorded Mar 26, 2026
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 074200/0818 →
SECURITY INTEREST
Recorded Mar 24, 2026
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 074172/0328 →
SECURITY INTEREST
Recorded Mar 24, 2026
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 074172/0698 →
SECURITY INTEREST
Recorded Mar 24, 2026
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS ADMINISTRATIVE AGENT
Reel/Frame 074172/0760 →
SECURITY INTEREST
Recorded Jun 25, 2025
From: REVOLUTION MEDICINES, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT
Reel/Frame 071721/0025 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 13, 2025
From: KOLTUN, ELENA S.; CREGG, JAMES; LIU, YANG; GILL, ADRIAN L.
To: REVOLUTION MEDICINES, INC.
Reel/Frame 071410/0138 →
Continuity (7)
Provisional Application
63192775
· May 25, 2021
Provisional Application
63184412
· May 5, 2021
Provisional Application
63129231
· Dec 22, 2020
Provisional Application
63078802
· Sep 15, 2020
References Cited (310)
US 6183965B1
· Verdine et al.
· 2001
[cited by applicant]
US 6372712B1
· Briesewitz et al.
· 2002
[cited by applicant]
US 6686454B1
· Yatscoff et al.
· 2004
[cited by applicant]
US 6713607B2
· Caggiano et al.
· 2004
[cited by applicant]
US 7220552B1
· Crabtree et al.
· 2007
[cited by applicant]
US 7396660B2
· Huang et al.
· 2008
[cited by applicant]
US 7851183B2
· Zotchev et al.
· 2010
[cited by applicant]
US 8664186B2
· Aigle et al.
· 2014
[cited by applicant]
US 9119853B2
· Moss et al.
· 2015
[cited by applicant]
US 9211291B2
· Berkenblit et al.
· 2015
[cited by applicant]
US 9250237B2
· Liu et al.
· 2016
[cited by applicant]
US 9260484B2
· Briesewitz et al.
· 2016
[cited by applicant]
US 9428845B1
· Verdine et al.
· 2016
[cited by applicant]
US 9989535B2
· Verdine et al.
· 2018
[cited by applicant]
US 20030153053A1
· Reid
· 2003
[cited by applicant]
US 20030175901A1
· Reeves et al.
· 2003
[cited by applicant]
US 20050233431A1
· Ashley et al.
· 2005
[cited by applicant]
US 20070203168A1
· Zhao
· 2007
[cited by applicant]
US 20120208720A1
· Kashiwagi et al.
· 2012
[cited by applicant]
US 20130072439A1
· Nash et al.
· 2013
[cited by applicant]
US 20180318434A1
· Verdine et al.
· 2018
[cited by applicant]
US 20200197391A1
· Jin et al.
· 2020
[cited by applicant]
US 20200199102A1
· Mulvihill et al.
· 2020
[cited by applicant]
US 20210285955A1
· Mulvihill et al.
· 2021
[cited by applicant]
US 20210405060A1
· Verdine et al.
· 2021
[cited by applicant]
US 20220143202A1
· Verdine et al.
· 2022
[cited by applicant]
US 20230100838A1
· Pitzen et al.
· 2023
[cited by applicant]
US 20230106174A1
· Koltun et al.
· 2023
[cited by applicant]
US 20230212152A1
· Arnold et al.
· 2023
[cited by applicant]
US 20230233569A1
· Singh et al.
· 2023
[cited by applicant]
US 20230374035A1
· Koltun et al.
· 2023
[cited by applicant]
US 20240084305A1
· Liu et al.
· 2024
[cited by applicant]
US 20240108630A1
· Corcoran et al.
· 2024
[cited by applicant]
US 20240139185A1
· Jin et al.
· 2024
[cited by applicant]
US 20240262847A1
· Burnett et al.
· 2024
[cited by applicant]
US 20240277796A1
· Seamon
· 2024
[cited by applicant]
US 20240352036A1
· Li et al.
· 2024
[cited by applicant]
US 20240352038A1
· Li et al.
· 2024
[cited by applicant]
US 20240368190A1
· Li et al.
· 2024
[cited by applicant]
US 20240383920A1
· Li et al.
· 2024
[cited by applicant]
US 20240426833A1
· Mulvihill et al.
· 2024
[cited by applicant]
US 20250009753A1
· Blaj et al.
· 2025
[cited by applicant]
US 20250041295A1
· Jiang et al.
· 2025
[cited by applicant]
US 20250049810A1
· Jiang et al.
· 2025
[cited by applicant]
US 20250051306A1
· Aggen et al.
· 2025
[cited by applicant]
US 20250074923A1
· Knox et al.
· 2025
[cited by applicant]
US 20250076289A1
· Verdine et al.
· 2025
[cited by applicant]
US 20250085291A1
· Verdine et al.
· 2025
[cited by applicant]
US 20250101031A1
· Verdine et al.
· 2025
[cited by applicant]
US 20250115551A1
· Li et al.
· 2025
[cited by applicant]
US 20250121077A1
· Verdine et al.
· 2025
[cited by applicant]
US 20250129097A1
· Cregg et al.
· 2025
[cited by applicant]
EP 0194972A2
· 1986
[cited by applicant]
EP 0393934A1
· 1990
[cited by applicant]
EP 0562853A1
· 1993
[cited by applicant]
KR 1020090041971A
· 2009
[cited by applicant]
WO WO8602080A1
· 1986
[cited by applicant]
WO WO9532294A1
· 1995
[cited by applicant]
WO WO9620216A1
· 1996
[cited by applicant]
WO WO9641807A1
· 1996
[cited by applicant]
WO WO9801546A2
· 1998
[cited by applicant]
WO WO9807743A1
· 1998
[cited by applicant]
WO WO9812217A1
· 1998
[cited by applicant]
WO WO0047724A2
· 2000
[cited by applicant]
WO WO0136460A2
· 2001
[cited by applicant]
WO WO0136612A1
· 2001
[cited by applicant]
WO WO0190070A2
· 2001
[cited by applicant]
WO WO03033010A1
· 2003
[cited by applicant]
WO WO2008069824A2
· 2008
[cited by applicant]
WO WO2010031185A1
· 2010
[cited by applicant]
WO WO2010034243A1
· 2010
[cited by applicant]
WO WO2010088573A1
· 2010
[cited by applicant]
WO WO2012078915A1
· 2012
[cited by applicant]
WO WO2012131371A1
· 2012
[cited by applicant]
WO WO2012131377A1
· 2012
[cited by applicant]
WO WO2013001310A1
· 2013
[cited by applicant]
WO WO2013022818A1
· 2013
[cited by applicant]
WO WO2013185090A1
· 2013
[cited by applicant]
WO WO2013185103A1
· 2013
[cited by applicant]
WO WO2014009774A1
· 2014
[cited by applicant]
WO WO2014121942A1
· 2014
[cited by applicant]
WO WO2014169167A1
· 2014
[cited by applicant]
WO WO2014176488A1
· 2014
[cited by applicant]
WO WO2014187959A2
· 2014
[cited by applicant]
WO WO2015132784A1
· 2015
[cited by applicant]
WO WO2016008011A1
· 2016
[cited by applicant]
WO WO2016033486A1
· 2016
[cited by applicant]
WO WO2016160362A1
· 2016
[cited by applicant]
WO WO2017058768A1
· 2017
[cited by applicant]
WO WO2017085198A1
· 2017
[cited by applicant]
WO WO2018081592A2
· 2018
[cited by applicant]
WO WO2018091634A1
· 2018
[cited by applicant]
WO WO2018217651A1
· 2018
[cited by applicant]
WO WO2020101736A1
· 2020
[cited by applicant]
WO WO2020106640A1
· 2020
[cited by applicant]
WO WO2021052499A1
· 2021
[cited by applicant]
WO WO2021086833A1
· 2021
[cited by applicant]
WO WO2022060583A1
· 2022
[cited by applicant]
WO WO2022137085A1
· 2022
[cited by applicant]
WO WO2022137174A1
· 2022
[cited by applicant]
WO WO2022139304A1
· 2022
[cited by applicant]
WO WO2022217053A1
· 2022
[cited by applicant]
WO WO2022235725A1
· 2022
[cited by applicant]
WO WO2022235945A1
· 2022
[cited by applicant]
WO WO2022271658A1
· 2022
[cited by applicant]
WO WO2023015559A1
· 2023
[cited by applicant]
WO WO2023025832A1
· 2023
[cited by applicant]
WO WO2023133543A1
· 2023
[cited by applicant]
WO WO2023240263A1
· 2023
[cited by applicant]
WO WO2024081363A1
· 2024
[cited by applicant]
WO WO2024102421A2
· 2024
[cited by applicant]
WO WO2024206858A1
· 2024
[cited by applicant]
WO WO2024211663A1
· 2024
[cited by applicant]
WO WO2024211712A1
· 2024
[cited by applicant]
WO WO2024229406A1
· 2024
[cited by applicant]
“On Target to Outsmart Cancer™,” Revolution Medicines (Jan. 11, 2022) (33 pages).
[cited by applicant]
“Registration No. 333-235968: Amendment No. 2 to Form S-1 Registration Statement Under The Securities Act of 1933 for Revolution Medicines, Inc.,” United States Securities and Exchange Commission, Washington, D.C., 2054…
[cited by applicant]
“SMART™ Drugs: Engineering Nature's Solution to the Undruggable Target Challenge,” WarpDrive Bio, 2016, available <http://www.warpdrivebio.com/docs/Warp%20Drive%20Bio_SMART%20Drugs%20Platform_2016.pdf> (31 pages).
[cited by applicant]
“
[cited by applicant]
“
[cited by applicant]
“Substructure Search Report on Specifically Substituted Macrocycles—Substances Only,” prepared by Science IP, dated Dec. 17, 2014 (6177 pages).
[cited by applicant]
“Translating Frontier Oncology Targets to Outsmart Cancer™,” Corporate Overview Q3-2020, Revolution Medicines, Aug. 20, 2020 (35 pages).
[cited by applicant]
Aebi et al., “Synthesis, Conformation, and Immunosuppressive Activities of Three Analogues of Cyclosporin A Modified in the 1-Position,” J Med Chem. 33(3):999-1009 (1990).
[cited by applicant]
Allain et al., “Cyclophilin B mediates cyclosporin A incorporation in human blood T-lymphocytes through the specific binding of complexed drug to the cell surface,” Biochem J. 317 (Pt 2):565-70 (1996).
[cited by applicant]
Andrei et al., “Stabilization of protein-protein interactions in drug discovery,” Expert Opin Drug Discov. 12(9):925-40 (2017) (17 pages).
[cited by applicant]
Antunes et al., “A mutational analysis defines Vibrio fischeri LuxR binding sites,” J Bacteriol. 190(13):4392-7 (2008).
[cited by applicant]
Araujo et al. “Mechanisms of response and tolerance to active RAS inhibition in KRAS-mutant NSCLC,” Cancer Discov. (Jul. 2024) (87 pages).
[cited by applicant]
Archibald et al., “Discovery and Evaluation of Potent, Cysteine-based alpha4beta1 Integrin Antagonists,” Bioorg Med Chem Lett. 10(9):993-995 (2000).
[cited by applicant]
Baillie, “Targeted Covalent Inhibitors for Drug Design,” Covalent Inhibitor Drug Discovery & Development Symposium PBSS, Feb. 7, Foster City, California. (2019) (16 pages).
[cited by applicant]
Banaszynski et al., “Characterization of the FKBP.rapamycin.FRB ternary complex,” J Am Chem Soc. 127(13):4715-21 (2005).
[cited by applicant]
Banteli et al., “A synthesis of the C1—N12 tripeptide fragment of sanglifehrin A,” Tetrahedron Letters. 40(11):2109-2112 (Mar. 12, 1999).
[cited by applicant]
Baranasic et al., “Draft Genome Sequence of
[cited by applicant]
Bastin et al., “Salt selection and optimisation procedures for pharmaceutical new chemical entities,” Org Process Res Dev 4(5):427-35 (2000).
[cited by applicant]
Bayle et al., “Rapamycin analogs with differential binding specificity permit orthogonal control of protein activity,” Chem Biol. 13(1):99-107 (2006).
[cited by applicant]
Bender et al., “Periodate Oxidation of alpha-Keto gamma-Lactams. Enol Oxidation and beta-Lactam Formation. Mechanism of Periodate Hydroxylation Reactions,” J Org Chem. 43(17):3354-3362 (1978).
[cited by applicant]
Benjamin et al., “Rapamycin passes the torch: a new generation of mTOR inhibitors,” Nat Rev Drug Discov. 10(11):868-80 (2011).
[cited by applicant]
Bhuyan et al., “Antioxidant activity of peptide-based angiotensin converting enzyme inhibitors,” Org Biomol Chem. 10(11):2237-47 (2012).
[cited by applicant]
Blodgett et al., “Unusual transformations in the biosynthesis of the antibiotic phosphinothricin tripeptide,” Nat Chem Biol. 3(8):480-5 (2007).
[cited by applicant]
Braun et al., “A bifunctional molecule that displays context-dependent cellular activity,” J Am Chem Soc. 125(25):7575-80 (Jun. 2003).
[cited by applicant]
Briesewitz et al., “Affinity modulation of small-molecule ligands by borrowing endogenous protein surfaces,” Proc Natl Acad Sci U.S.A. 96(5):1953-8 (1999).
[cited by applicant]
Bruce, “In vivo protein complex topologies: sights through a cross-linking lens,” Proteomics. 12(10):1565-75 (2012).
[cited by applicant]
Burgess et al., “Controlled translocation of palladium(II) within a 22 ring atom macrocyclic ligand,” Dalton Trans. 43(45):17006-16 (2014) (12 pages).
[cited by applicant]
Chaurasia et al., “Molecular insights into the stabilization of protein-protein interactions with small molecule: The FKBP12-rapamycin-FRB case study,” Chem Phys Lett. 587:68-74 (2013).
[cited by applicant]
Che et al., “Inducing protein-protein interactions with molecular glues,” Bioorg Med Chem Lett. 28(15):2585-92 (Aug. 2018) (18 pages).
[cited by applicant]
Chen et al., “Adaptive and Reversible Resistance to Kras Inhibition in Pancreatic Cancer Cells,” Cancer Res. 78(4): 985-1002 (19 pages) (Feb. 2018).
[cited by applicant]
Chen et al., “Emerging strategies to target RAS signaling in human cancer therapy,” J Hematol Oncol. 14(1):116 (Jul. 23, 2021) (23 pages).
[cited by applicant]
Chevalier et al., “Straightforward synthesis of bioconjugatable azo dyes. Part 1: Black Hole Quencher-1 (BHQ-1) scaffold,” Tetrahedron Lett. 55(50):6759-63 (2014).
[cited by applicant]
Choi et al., “Challenges in Ras therapeutics in pancreatic cancer,” Semin Cancer Biol. 54: 101-108 (8 pages) (Feb. 2019).
[cited by applicant]
Ding et al., “Insights into Bacterial 6-Methylsalicylic Acid Synthase and Its Engineering to Orsellinic Acid Synthase for Spirotetronate Generation,” Chem Biol. 17(5):495-503 (2010).
[cited by applicant]
Doak et al., “Cyclophilin Succumbs to a Macrocyclic Chameleon,” J Med Chem. 61(21):9469-9472 (Nov. 2018).
[cited by applicant]
Dyson et al., Chemistry of synthetic medicines. May's Chemistry of Synthetic Drugs, Fifth Edition. Moscow: Mir. pp. 12-19 (1964) (9 Pages).
[cited by applicant]
Eberle et al., “Preparation of Functionalized Ethers of Cyclosporin A,” Tetrahedron Lett. 35(35):6477-6480 (1994).
[cited by applicant]
Findlay et al., “The structure of demethoxyrapamycin,” Can J Chem. 60:2046-7 (1982).
[cited by applicant]
Garg et al., “Elucidation of the Cryptic Epimerase Activity of Redox-Inactive Ketoreductase Domains from Modular Polyketide Synthases by Tandem Equilibrium Isotope Exchange,” J Am Chem Soc. 136(29):10190-10193 (2014).
[cited by applicant]
Gill et al., “Discovery of Small Molecule Inhibitors of the Oncogenic, GTP-Bound (ON) Form of KRASG12C and KRASG13C,” Revolution Medicines (Sep. 2019) (1 page).
[cited by applicant]
Gill, “Discovery of Small Molecule Inhibitors of Oncogenic Mutants of RAS,” Revolution Medicines, ACS, Apr. 2, Orlando (2019) (23 pages).
[cited by applicant]
Gordon et al., “A SARS-CoV-2 Protein Interaction Map Reveals Targets for Drug Repurposing,” Nature. 583(7816):459-68 (Apr. 2020).
[cited by applicant]
Guerra et al., “LAL regulators SCO0877 and SCO7173 as pleiotropic modulators of phosphate starvation response and actinorhodin biosynthesis in
[cited by applicant]
Guo et al., “Rapamycin-inspired macrocycles with new target specificity,” Nat Chem. 11(3):254-263 (Mar. 2019) (13 pages).
[cited by applicant]
Halford, “Covalent drugs go from fringe field to fashionable endeavor: Designing molecules that make bonds with their biological targets is in vogue,” Chemical and Engineering News, 98(43) (Nov. 2020) (6 pages).
[cited by applicant]
Hansson et al., “Bioengineering and Semisynthesis of an Optimized Cyclophilin Inhibitor for Treatment of Chronic Viral Infection,” Chem Biol. 22(2):285-92 (2015) (24 pages).
[cited by applicant]
He et al., “The LuxR family members GdmRI and GdmRII are positive regulators of geldanamycin biosynthesis in
[cited by applicant]
Hoffman, “The origins and evolution of “controlled” drug delivery systems,” J Control Release. 132(3):153-63 (Dec. 2008) (Epub Aug. 2008).
[cited by applicant]
Holderfield et al. “Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy,” Nature. 629(8013):919-926 (May 2024) (33 pages) (supplementary information included).
[cited by applicant]
Hong et al., “Evidence for an iterative module in chain elongation on the azalomycin polyketide synthase,” Beilstein J Org Chem. 12:2164-2172 (2016).
[cited by applicant]
Horn et al., “Draft Genome Sequence of
[cited by applicant]
Horton et al., “Engineering hybrid genes without the use of restriction enzymes: gene splicing by overlap extension,” Gene. 77(1):61-8 (1989).
[cited by applicant]
Hosted et al., “Use of rpsL for dominance selection and gene replacement in
[cited by applicant]
Huang et al., “Conjugation to Albumin-Binding Molecule Tags as a Strategy to Improve Both Efficacy and Pharmacokinetic Properties of the Complement Inhibitor Compstatin,” ChemMedChem. 9(10):2223-6 (2014).
[cited by applicant]
Huang et al., “Enhanced rapamycin production in
[cited by applicant]
Hubler et al., “Synthetic routes to NEtXaa4-cyclosporin A derivatives as potential anti-HIV I drugs,” Tetrahedron Lett. 41:7193-6 (2000).
[cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2021/050454, mailed Dec. 23, 2021 (13 pages).
[cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2022/027770, mailed Aug. 12, 2022 (15 pages).
[cited by applicant]
International Search Report and Written Opinion for International Patent Application No. PCT/US2022/027778, mailed Jul. 4, 2022 (12 pages).
[cited by applicant]
Ishizawa et al., “TRAP display: a high-speed selection method for the generation of functional polypeptides,” J Am Chem. 135(14):5433-40 (2013).
[cited by applicant]
Janes et al., “Targeting KRAS Mutant Cancers with a Covalent G12C-Specific Inhibitor,” Cell., 172(3):578-589.e17 (Jan. 2018) (30 pages).
[cited by applicant]
Jarvis, “Have drug hunters finally cracked KRas?—After decades of failures, researchers see promise in fresh approaches to developing drugs that block cancer's toughest target,” Chemical & Engineering News. 94(23):28-33…
[cited by applicant]
Jiang et al. “Translational and Therapeutic Evaluation of RAS-GTP Inhibition by RMC-6236 in RAS-Driven Cancers,” Cancer Discov. 14(6):994-1017 (Jun. 2024) (39 pages) (supplemental information included).
[cited by applicant]
Kawakami et al., “In vitro selection of multiple libraries created by genetic code reprogramming to discover macrocyclic peptides that antagonize VEGFR2 activity in living cells,” ACS Chem Biol. 8(6):1205-14 (2013).
[cited by applicant]
Kelsey, “Approaches to Inhibiting RAS-Driven Tumors Beyond KRASG12C,” RAS Targeted Drug Development, Revolution Medicines, Sep. 16 2020 (24 pages).
[cited by applicant]
Kelsey, “Discovery and Development of RAS(ON) Inhibitors Beyond KRASG12C,” AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics, Oct. 7-10, Redwood City, California (Oct. 2021) (2…
[cited by applicant]
Kendrew et al., “Recombinant strains for the enhanced production of bioengineered rapalogs,” Metab Eng. 15:167-73 (2013).
[cited by applicant]
Koltun et al., “Drugging the RAS(ON) Form of Diverse Oncogenic RAS Mutations,” 21st RSC / SCI Medicinal Chemistry Symposium, Sep. 15, Cambridge, Massachusetts (Sep. 2021) (35 Pages).
[cited by applicant]
Koltun et al., “First-in-class, orally bioavailable KRASG12V (ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12V mutant cancers,” Ameri…
[cited by applicant]
Koltun et al., “First-in-class, orally bioavailable KRASG12V(ON)/RASMULTI(ON) tri-complex inhibitors, as single agents and in combinations, drive profound anti-tumor activity in preclinical models of KRASG12V mutant can…
[cited by applicant]
Kuhn et al., “Synthesis of Functional Ras Lipoproteins and Fluorescent Derivatives,” J Am Chem Soc. 123(6):1023-35 (2001).
[cited by applicant]
Kummerer, “Pharmaceuticals in the Environment,” Annual Review of Environment and Resources. 35:57-75 (Nov. 2010) (Epub Aug. 18, 2010).
[cited by applicant]
Kuramochi et al., “Identification of Small Molecule Binding Molecules by Affinity Purification Using a Specific Ligand Immobilized on PEGA Resin,” Bioconjug Chem. 19(12):2417-26 (2008).
[cited by applicant]
Laureti et al., “Identification of a bioactive 51-membered macrolide complex by activation of a silent polyketide synthase in
[cited by applicant]
Laureti et al., Supporting Material for “Identification of a bioactive 51-membered macrolide complex by activation of a silent polyketide synthase in
[cited by applicant]
Lee et al., “Current implications of cyclophilins in human cancers,” J Exp Clin Cancer Res. 29(1):97 (2010) (6 pages).
[cited by applicant]
Leskiw et al., “TTA codons in some genes prevent their expression in a class of developmental, antibiotic-negative,
[cited by applicant]
Li et al., “A simple and efficient route to the FKBP-binding domain from rapamycin,” available in PMC Sep. 28, 2012, published in final edited form as: Tetrahedron Lett. 52(39):5070-2 (2011) (7 pages).
[cited by applicant]
Luengo et al., “Structure-activity studies of rapamycin analogs: evidence that the C-7 methoxy group is part of the effector domain and positioned at the FKBP12-FRAP interface,” Chem Biol. 2(7):471-81 (1995).
[cited by applicant]
Mackman et al., “Discovery of a Potent and Orally Bioavailable Cyclophilin Inhibitor Derived from the Sanglifehrin Macrocycle,” J Med Chem. 61(21):9473-9499 ( Aug. 2018).
[cited by applicant]
Majumder et al. “Interaction of aryl hydrocarbon receptor-interacting protein-like 1 with the farnesyl moiety,” J Biol Chem. 288(29):21320-21328 (2013).
[cited by applicant]
McGregor et al., “Expanding the Scope of Electrophiles Capable of Targeting K-Ras Oncogenes,” Biochemistry. 56(25):3178-3183 (2017).
[cited by applicant]
Meyer et al., “Selective palladation of a large (32 ring atom) macrocyclic ligand at a bis(N-heterocyclic carbene) coordination pocket through transmetallation of the corresponding mercury(II) derivative,” Dalton Trans.…
[cited by applicant]
Mo et al., “Interspecies Complementation of the LuxR Family Pathway-Specific Regulator Involved in Macrolide Biosynthesis,” J Microbiol Biotechnol. 26(1):66-71 (2016).
[cited by applicant]
Moore et al., “RAS-targeted therapies: is the undruggable drugged?” available in PMC Feb. 1, 2021, published in final edited form as: Nat Rev Drug Discov. 19(8):533-52 (Aug. 2020) (43 pages).
[cited by applicant]
Mullard, “Cracking KRAS,” Nat Rev Drug Discov. 18(12):887-91 (Nov. 2019) (14 pages).
[cited by applicant]
Murphy et al., “Isolation and characterisation of amphotericin B analogues and truncated polyketide intermediates produced by genetic engineering of
[cited by applicant]
Ochi et al., “New strategies for drug discovery: activation of silent or weakly expressed microbial gene clusters,” Appl Microbiol Biotechnol. 97(1):87-98 (2013).
[cited by applicant]
Ostrem et al., “Direct small-molecule inhibitors of KRAS: from structural insights to mechanism-based design,” Nat Rev Drug Discov. 15(11):771-785 (2016).
[cited by applicant]
Ostrem et al., “K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions,” Nature. 503(7477):548-51 (2013) (14 pages).
[cited by applicant]
Papageorgiou et al., “Improved binding affinity for cyclophilin A by a cyclosporin derivative singly modified at its effector domain,” J Med Chem. 37(22):3674-6 (1994).
[cited by applicant]
Pei et al., “Targeting Ras with Macromolecules,” Cold Spring Harb Perspect Med. 8(3):a031476 (Mar. 2018) (14 pages).
[cited by applicant]
Pfeifer et al., “Biosynthesis of complex polyketides in a metabolically engineered strain of
[cited by applicant]
Pollock et al., “Development of Inhibitors of the Activated Form of KRASG12C,” AACR Targeting RAS-Driven Cancers, Dec. 9-12, San Diego, California (Dec. 2018) (Abstract Included) (2 pages).
[cited by applicant]
Power et al., “Engineered Synthesis of 7-Oxo- and 15-Deoxy-15-Oxo-Amphotericins: Insights into Structure-Activity Relationships in Polyene Antibiotics,” Chem Biol. 15(1):78-86 (2008).
[cited by applicant]
PubChem CID 130196149, <https://pubchem.ncbi.nlm.nih.gov/compound/130196149>, retrieved on Apr. 1, 2020 (10 pages).
[cited by applicant]
Quesniaux et al., “Cyclophilin binds to the region of cyclosporine involved in its immunosuppressive activity,” Eur J Immunol. 17(9):1359-65 (1987).
[cited by applicant]
Quesniaux et al., “Study of the conformation of cyclosporine in aqueous medium by means of monoclonal antibodies,” Int J Pept Protein Res. 31(2):173-85 (1988).
[cited by applicant]
Ranganathan et al., “Knowledge-based design of bimodular and trimodular polyketide synthases based on domain and module swaps: a route to simple statin analogues,” Chem Biol. 6(10):731-41 (1999).
[cited by applicant]
Ray et al., “New Electrophiles and Strategies for Mechanism-Based and Targeted Covalent Inhibitor Design,” Biochemistry. 58: 5234-5244 (Dec. 2019).
[cited by applicant]
Reid et al. “A model of structure and catalysis for ketoreductase domains in modular polyketide synthases,” Biochemistry. 42(1):72-79 (2003).
[cited by applicant]
Revill et al., “Genetically engineered analogs of ascomycin for nerve regeneration,” J Pharmacol Exp Ther. 302(3):1278-85 (2002).
[cited by applicant]
Revolution Medicines, “Corporate Overview Q1 2021,” Translating Frontier Oncology Targets to Outsmart Cancer™ (Apr. 30, 2021) (35 pages).
[cited by applicant]
Revolution Medicines, “Corporate Overview Q1 2021,” Translating Frontier Oncology Targets to Outsmart Cancer™ (Mar. 2, 2021) (35 pages).
[cited by applicant]
Revolution Medicines, “Corporate Overview Q1-2021,” Translating Frontier Oncology Targets to Outsmart Cancer™ (Jan. 12, 2021) (34 pages).
[cited by applicant]
Revolution Medicines, “Corporate Overview Q2 2021,” Translating Frontier Oncology Targets to Outsmart Cancer™ (May 10, 2021) (34 pages).
[cited by applicant]
Revolution Medicines, “Corporate Overview,” Translating Frontier Oncology Targets to Outsmart Cancer™ (Aug. 11, 2021) (43 pages).
[cited by applicant]
Revolution Medicines, “Corporate Overview,” Translating Frontier Oncology Targets to Outsmart Cancer™ (Feb. 8, 2021) (35 pages).
[cited by applicant]
Revolution Medicines, “Drugging the RAS(ON) Form of Diverse Oncogenic RAS Mutations,” RAS Targeted Drug Discovery: Expanding RAS Druggability Beyond G12C (Feb. 2021) (24 pages).
[cited by applicant]
Revolution Medicines, “RMC-6291: Biological Features of Targeting KRASG12C(ON) and Potential Application to Overcoming Drug Resistance in RAS-Addicted Tumors,” dated May 26, 2021 (17 pages).
[cited by applicant]
Revolution Medicines, “Translating Frontier Oncology Targets to Outsmart Cancer™: Corporate Overview Q4-2020,” dated Nov. 12, 2020 (30 pages).
[cited by applicant]
Ruan et al., “Binding of rapamycin analogs to calcium channels and FKBP52 contributes to their neuroprotective activities,” Proc Natl Acad Sci U S A. 105(1):33-8 (2008).
[cited by applicant]
Rudolph, “Covalent Modification in Drug Discovery—A Chemist's Perspective,” Pharmaceutical & BioScience Society. Dated Feb. 7, 2019 (39 pages).
[cited by applicant]
Saeidian et al., “Effect of aromaticity and ring strain on proton affinity of aziridine and amidine skeletons: a DFT study,” Journal of the Iranian Chemical Society. 17:1731-1741 (Mar. 2020).
[cited by applicant]
Sànchez-Tilló et al., “Cyclophilin A is required for M-CSF-dependent macrophage proliferation,” Eur J Immunol. 36(9):2515-24 (2006).
[cited by applicant]
Schulze et al. “Chemical remodeling of a cellular chaperone to target the active state of mutant KRAS,” Science. 381(6659):794-799 (Aug. 2023) (79 pages) (supplemental information included).
[cited by applicant]
Schulze et al., “Tri-Complex Inhibitors of the Oncogenic, GTP-Bound Form of KRASG12C Overcome RTK-Mediated Escape Mechanisms and Drive Tumor Regressions in Vivo,” Revolution Medicines (Oct. 2019) (1 page).
[cited by applicant]
Schutt, “Safety Considerations for Covalent Inhibitors,” Pharmaceutical & BioScience Society. Dated Feb. 7, 2019 (36 pages).
[cited by applicant]
Schwecke et al., “The biosynthetic gene cluster for the polyketide immunosuppressant rapamycin,” Proc Natl Acad Sci U S A. 92(17):7839-43 (1995).
[cited by applicant]
Sebastiano et al., “Impact of Dynamically Exposed Polarity on Permeability and Solubility of Chameleonic Drugs Beyond the Rule of 5,” J Med Chem. 61:4189-4202 (Apr. 2018).
[cited by applicant]
Shigdel et al., “Genomic discovery of an evolutionarily programmed modality for small-molecule targeting of an intractable protein surface,” Proc Natl Acad Sci U S A. 117(29):17195-203 (Jul. 2020).
[cited by applicant]
Sieber et al., “Novel inhibitors of the calcineurin/NFATc hub—alternatives to CsA and FK506?” Cell Commun Signal. 7:25 (2009) (19 pages).
[cited by applicant]
Sieburth et al., “SUR-8, a conserved Ras-binding protein with leucine-rich repeats, positively regulates Ras-mediated signaling in C. elegans,” Cell. 94(1):119-30 (Jul. 1998).
[cited by applicant]
Simanshu et al., “RAS Proteins and Their Regulators in Human Disease,” available in PMC Jun. 29, 2018, published in final edited form as: Cell. 170(1):17-33 (2017) (34 pages).
[cited by applicant]
Smith, “Translating Frontier Oncology Targets to Outsmart Cancer,” RAS-Targeted Drug Discovery Summit, Revolution Medicines, Sep. 19 (2019) (29 pages).
[cited by applicant]
Smulik et al., “Synthesis of cyclosporin A-derived affinity reagents by olefin metathesis,” Org Lett. 4(12):2051-4 (2002).
[cited by applicant]
Steadman et al., “Discovery of Potent Cyclophilin Inhibitors Based on the Structural Simplification of Sanglifehrin A,” J Med Chem. 60:1000-1017 (2017).
[cited by applicant]
Stewart et al., “Development of Inhibitors of the Activated Form of KRASG12C,” AACR Targeting RAS-Driven Cancers, Dec. 9-12, San Diego, California. Poster B37 (2018) (1 page).
[cited by applicant]
STN record of WO 2014/009774, available online Jan. 16, 2014 (4 pages).
[cited by applicant]
STN record of WO 98/12217, available online Mar. 26, 1998 (6 pages).
[cited by applicant]
Sun et al. “Design and structure-based study of new potential FKBP12 inhibitors,” Biophys J. 85(5):3194-3201 (2003).
[cited by applicant]
Sweeney et al., “From chemical tools to clinical medicines: non-immunosuppressive cyclophilin inhibitors derived from the cyclosporin and sanglifehrin scaffolds,” J Med Chem. 57(17):7145-59 (2014) (63 pages).
[cited by applicant]
Takakusagi et al., “Efficient one-cycle affinity selection of binding proteins or peptides specific for a small-molecule using a T7 phage display pool,” Bioorg Med Chem. 16(22):9837-46 (2008).
[cited by applicant]
Tanaka et al., “Clinical Acquired Resistance to KRASG12C Inhibition through a Novel KRAS Switch-II Pocket Mutation and Polyclonal Alterations Converging on RAS-MAPK Reactivation,” Cancer Discov. 11(8):1913-1922 (Apr. 6,…
[cited by applicant]
Tang et al., “Generation of New Epothilones by Genetic Engineering of a Polyketide Synthase in
[cited by applicant]
UniProtKB Accession No. A0A061A6I8, Sep. 3, 2014, available <http://www.uniprot.org/uniprot/A0A061A6I8>, (12 pages).
[cited by applicant]
UniProtKB Accession No. Q54296, “Polyketide synthase,” <https://www.uniprot.org/uniprot/A0A61A6I8.txt?version=14>, retrieved May 29, 2020 (12 pages).
[cited by applicant]
UniProtKB Accession No. Q54296, Nov. 1, 1996, available <http://www.uniprot.org/uniprot/Q54296>, (12 pages).
[cited by applicant]
UniProtKB Accession No. Q54297, Nov. 1, 1996, available <https://www.uniprot.org/uniprot/Q54297.txt>, (3 pages).
[cited by applicant]
Upadhyaya et al., “Direct Ras Inhibitors Identified From a Structurally Rigidified Bicyclic Peptide Library,” available in PMC Oct. 21, 2015, published in final edited form as: Tetrahedron. 70(42):7714-7720 (2014) (15 p…
[cited by applicant]
Vakiti et al., “Stereoselective synthesis of C17—C34 fragment of antascomicin A,” Tetrahedron Lett. 55(47):6438-40 (2014).
[cited by applicant]
Vignot et al., “mTOR-targeted therapy of cancer with rapamycin derivatives,” Ann Oncol. 16(4):525-37 (2005).
[cited by applicant]
Vocadlo et al. “Mechanistic insights into glycosidase chemistry,” Curr Opin Chem Biol. 12:539-555 (2008) (17 pages).
[cited by applicant]
Wagner et al., “New naturally occurring amino acids,” Angew Chem Int Ed Engl. 22(11):816-28 (1983).
[cited by applicant]
Wang et al., “Thermodynamic analysis of cyclosporin a binding to cyclophilin a in a lung tumor tissue lysate,” Anal Chem. 76(15):4343-8 (2004).
[cited by applicant]
Wasko et al. “Tumour-selective activity of RAS-GTP inhibition in pancreatic cancer,” Nature. 629(8013):927-936 (May 2024) (31 pages).
[cited by applicant]
Weissman et al., “Combinatorial biosynthesis of reduced polyketides,” Nat Rev Microbiol. 3(12):925-36 (2005).
[cited by applicant]
Weissman, “Genetic engineering of modular PKSs: from combinatorial biosynthesis to synthetic biology,” Nat Prod Rep. 33(2):203-230 (2016).
[cited by applicant]
Wildes et al., “Inhibition of the Oncogenic, GTP-Bound Form of KRASG12C by Second Generation, Tri-Complex Inhibitors Overcomes RTK-Mediated Escape Mechanisms,” The FASEB Regulation and Function of Small GTPases Conferen…
[cited by applicant]
Wilson et al., “Comparative X-ray structures of the major binding protein for the immunosuppressant FK506 (tacrolimus) in unliganded form and in complex with FK506 and rapamycin,” Acta Cryst. D51:511-21 (1995).
[cited by applicant]
Wright et al., “Multivalent binding in the design of bioactive compounds,” Curr Org Chem. 5(11):1107-31 (2001).
[cited by applicant]
Wu et al., “Creating diverse target-binding surfaces on FKBP12: synthesis and evaluation of a rapamycin analogue library,” available in PMC Sep. 12, 2012, published in final edited form as: ACS Comb Sci. 13(5):486-95 (2…
[cited by applicant]
Wu et al., “Inhibition of ras-effector interactions by cyclic peptides,” Med Chem Commun. 4(2):378-82 (2013).
[cited by applicant]
Wu et al., “Synthesis of Ketone Analogues of Prolyl and Pipecolyl Ester FKBP12 Ligands,” J Med Chem. 45(16):3558-3568 (2002).
[cited by applicant]
Zhang et al., “Bifunctional Small-Molecule Ligands of K-Ras Induce Its Association with Immunophilin Proteins,” Angew Chem Int Ed Engl. 131:16460-5 (Nov. 2019).
[cited by applicant]
Zhou et al., “Biophysical and biochemical characterization of KRASG12C inhibition through a novel modality,” AACR Targeting RAS-Driven Cancers, Dec. 9-12, San Diego, California. Poster A06 (2018) (1 page).
[cited by applicant]
U.S. Appl. No. 19/196,483, Cregg et al.
[cited by applicant]